REMEGENIX - Key Persons
Job Titles:
- Interim Vice President of Business Development /
Strong international investment banking experience across several sectors (Biotech, energy, IT) with an excess of $50M of direct deal flow experience.
Co-founder of Lamiel Partners, focused on creating value in biotech through creative financing, deal flow and business development
Former Landmark Ventures associate, directly responsible for executing term sheet, partnerships and funding
Former Go4Venture Analyst, predominantly focused on fundraising and business plan development
Job Titles:
- Chairman
- Co - Founder
- Member of the Board of Directors
- Co - Founder, Chairman /
Initially trained as a cellular immunologist in Medical School, he then when on to use applied molecular and biochemical approaches to various immunological phenomenon, and led his lab at NIH to develop the "Death Trap", a screening system used to identify genes involved in T Cell Apoptosis. The third gene identified was involved in Alzheimer's disease, and thus started his interest in neurodegeneration. In the last 18 years, Dr. D'Adamio has developed an extensive background covering immunology, molecular biology, clinical neurology, cell biology, and biochemistry, and have demonstrated expertise in techniques spanning mouse genetic manipulation, biochemistry, molecular biology, behavior, electrophysiology, and cellular immunology.
Dr. D'Adamio's laboratory is exploring the pathogenesis of human dementias using an approach that is unusual, using animal models that have been generated by his laboratory and that were inspired by a pathogenic hypothesis that is different from that followed by the large majority of his fellow scientist in this field.
Job Titles:
- CEO
- Member of the Board of Directors
- President
- Co - Founder, President, Chief Executive Officer /
With 18+ years of experience in the life science, venture capital and IT sectors, Mr. Ganjei's expertise, focused on the inter-relationship of science, IT and entrepreneurship, has led to the creation of more than 7 businesses. He has led a number of regenerative medicine technologies in various stages of development throughout his career, and has a track record of putting together innovative relationships across the world including the UK, South Korea, Italy, Finland, New Zealand and Australia.
Collectively, Mr. Ganjei has demonstrated expertise in both the technical and business aspects of leading edge scientific research, and defines the term "effective multitasking". He has shown the business acumen to both conceptualize and execute a number of creative and successful deals resulting in substantial increases in shareholder value. He has published numerous scientific, peer-reviewed and industry-specific articles in a number of journals and has been an invited guest speaker and presenter at various business forums across the world. Over the years, Mr. Ganjei has held numerous senior executive or C-level roles within the areas of information technology, product development, sales, marketing, business development, and venture capital and has been co-founder and/or co-owner of 5 companies in 2 industry sectors and 2 countries.
Job Titles:
- Founder of Practical IP Strategy
Reid Adler is the founder of Practical IP Strategy, which advises life science enterprises in strategic planning, IP strategies, and technology transfer.
Reid also provides "virtual general counsel" support to technology companies and nonprofits through the Law Office of Reid Adler.
Additionally, he is a founder and the CEO of FasterContracts, a new software-as-service business devoted to accelerating and facilitating the negotiation of business agreements.